These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 25011978)

  • 21. Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.
    Kinney AY; Howell R; Ruckman R; McDougall JA; Boyce TW; Vicuña B; Lee JH; Guest DD; Rycroft R; Valverde PA; Gallegos KM; Meisner A; Wiggins CL; Stroup A; Paddock LE; Walters ST
    Contemp Clin Trials; 2018 Oct; 73():123-135. PubMed ID: 30236776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.
    Pal T; Vadaparampil ST
    Cancer Control; 2012 Oct; 19(4):255-66. PubMed ID: 23037493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
    Meaney-Delman D; Bellcross CA
    Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-counseling education for low literacy women at risk of Hereditary Breast and Ovarian Cancer (HBOC): patient experiences using the Cancer Risk Education Intervention Tool (CREdIT).
    Joseph G; Beattie MS; Lee R; Braithwaite D; Wilcox C; Metrikin M; Lamvik K; Luce J
    J Genet Couns; 2010 Oct; 19(5):447-62. PubMed ID: 20490636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
    Kotnik U; Peterlin B; Lovrecic L
    BMC Cancer; 2021 Jun; 21(1):665. PubMed ID: 34082720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mainstreaming genetic counseling for
    Verma A; Nag S; Hasan Q; Selvakumar VPP
    Indian J Cancer; 2019 Nov; 56(Supplement):S38-S47. PubMed ID: 31793441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors.
    Berliner JL; Fay AM;
    J Genet Couns; 2007 Jun; 16(3):241-60. PubMed ID: 17508274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Genetic Counseling of HBOC and Japanese Organization of HBOC].
    Fukushima Y
    Gan To Kagaku Ryoho; 2017 Feb; 44(2):107-110. PubMed ID: 28223668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system.
    Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
    Clin Genet; 2022 Mar; 101(3):324-334. PubMed ID: 34927729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.
    Flores KG; Steffen LE; McLouth CJ; Vicuña BE; Gammon A; Kohlmann W; Vigil L; Dayao ZR; Royce ME; Kinney AY
    J Genet Couns; 2017 Jun; 26(3):480-490. PubMed ID: 27496122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic Counselors' Experiences and Interest in Telegenetics and Remote Counseling.
    Zierhut HA; MacFarlane IM; Ahmed Z; Davies J
    J Genet Couns; 2018 Apr; 27(2):329-338. PubMed ID: 29362948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
    Gill G; Beard C; Storey K; Taylor S; Sexton A
    Psychooncology; 2020 Aug; 29(8):1303-1311. PubMed ID: 32497346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Second-Class Status?" Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome.
    Suttman A; Pilarski R; Agnese DM; Senter L
    J Genet Couns; 2018 Aug; 27(4):885-893. PubMed ID: 29404823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Japanese women's reasons for accompaniment status to hereditary breast and ovarian cancer-focused genetic counseling.
    Matsukawa M; Torishima M; Satoh C; Honda S; Kosugi S
    J Genet Couns; 2022 Apr; 31(2):497-509. PubMed ID: 34661949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer.
    Jacobs AS; Schwartz MD; Valdimarsdottir H; Nusbaum RH; Hooker GW; DeMarco TA; Heinzmann JE; McKinnon W; McCormick SR; Davis C; Forman AD; Lebensohn AP; Dalton E; Tully DM; Graves KD; Similuk M; Kelly S; Peshkin BN
    Fam Cancer; 2016 Oct; 15(4):529-39. PubMed ID: 26969308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementing mainstream genetic counseling within the area-wide network of the German Consortium Hereditary Breast and Ovarian Cancer (GC-HBOC): Satisfaction of primary care providers with the provided state-of-the-art training by the Cologne Center.
    Herold N; Bredow K; Ernst C; Tüchler A; Blümcke B; Waha A; Keser E; Hauke J; Wappenschmidt B; Hahnen E; Schmutzler RK; Rhiem K
    J Genet Couns; 2024 Feb; 33(1):206-215. PubMed ID: 38351721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A descriptive study of BRCA1 testing and reactions to disclosure of test results.
    Lynch HT; Lemon SJ; Durham C; Tinley ST; Connolly C; Lynch JF; Surdam J; Orinion E; Slominski-Caster S; Watson P; Lerman C; Tonin P; Lenoir G; Serova O; Narod S
    Cancer; 1997 Jun; 79(11):2219-28. PubMed ID: 9179070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hereditary breast and ovarian cancer: what the primary care physician should know.
    Khoury-Collado F; Bombard AT
    Obstet Gynecol Surv; 2004 Jul; 59(7):537-42. PubMed ID: 15199272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
    Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
    Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.